Two cyclic opioid peptide prodrugs were successfully stabilized against gut enzyme degradation but failed to achieve oral absorption because intestinal efflux transporters (P-glycoprotein) actively pumped them back out, revealing a dual challenge for oral peptide drug delivery.
Stable to CYP enzymes but blocked by P-glycoproteinSolving one barrier to oral peptide absorption isn't enough — efflux transporters independently prevented intestinal uptake of metabolically stable cyclic peptide prodrugs
What the researchers found
Two new cyclic prodrugs of enkephalin opioid peptides (CA-[Cha(4), D-Leu(5)]-Enk and CA-[Cha(4), D-Ala(5)]-Enk) were designed and characterized:
- Structural success: NMR and molecular dynamics showed type I β-turn conformations favorable for transcellular permeation
- Physicochemical success: Higher lipophilicity than linear peptides (better for cell crossing)
- Metabolic success: Stable to cytochrome P-450 oxidative metabolism in intestinal mucosa
- Absorption failure: Caco-2 cell studies revealed the prodrugs are substrates for P-glycoprotein and other apically polarized efflux transporters
- In vivo confirmation: Rat intestinal perfusion confirmed poor intestinal permeation
Conclusion: Oral absorption of cyclic peptide prodrugs requires designing molecules that avoid both CYP enzyme metabolism AND efflux transporter recognition.
Why it matters
Most peptide drugs must be injected because they can't survive oral delivery. This is a major barrier to patient compliance — imagine if insulin or GLP-1 drugs could simply be swallowed. This study identifies a critical lesson: even when you solve the enzyme degradation problem, efflux transporters can independently block absorption. Understanding that oral peptide delivery requires overcoming both barriers simultaneously is essential for designing the next generation of oral peptide drugs.
How the study worked
The two cyclic prodrugs were characterized using two-dimensional NMR spectroscopy for solution conformation and molecular dynamics simulations for structural analysis. Physicochemical properties (molecular surface area, cLog P) were calculated. Caco-2 cell monolayer permeation studies assessed transcellular transport and identified efflux transporter substrate activity. An in situ rat intestinal perfusion model validated intestinal permeation and metabolic stability in vivo.
What this study cannot tell us
Only two specific cyclic prodrugs were tested, so the findings may not generalize to all cyclic peptides. Caco-2 cells are an imperfect model of human intestinal epithelium. The rat perfusion model may not perfectly predict human oral absorption. The study focuses on the barriers to absorption but doesn't propose solutions for the efflux transporter problem. The opioid peptide backbone used may have unique transporter recognition features not shared by other therapeutic peptides.
How to read the evidence
This is a well-designed pharmaceutical sciences study using complementary in vitro (NMR, Caco-2) and in vivo (rat perfusion) methods. The negative finding (poor absorption despite metabolic stability) is clearly demonstrated and provides important design guidance for the field.
When this study was published
Published in 2012, this study's lessons about efflux transporter barriers remain highly relevant. The dual challenge it identified continues to drive oral peptide drug design strategies over a decade later.
The bigger picture
The quest for oral peptide drugs is one of the most active areas in pharmaceutical research. Oral semaglutide (Rybelsus) achieved this for one GLP-1 peptide using an absorption enhancer, but a general solution remains elusive. This study's identification of efflux transporters as an independent barrier, separate from enzymatic degradation, has influenced subsequent design strategies. Modern approaches now aim to simultaneously address enzyme stability, membrane permeability, AND transporter evasion — a challenge this study helped define.
Questions still open
- Can cyclic peptide prodrugs be further modified to evade P-glycoprotein recognition while maintaining metabolic stability?
- Would co-administration with P-glycoprotein inhibitors improve oral absorption of these cyclic peptide prodrugs?
- Are there structural design rules that predict efflux transporter substrate activity for cyclic peptides?
Common questions
Why can't most peptide drugs be taken as pills?
What is P-glycoprotein and why does it block peptide absorption?
Read the original research
Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: Characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P-450 enzymes in the intestinal mucosa.
Journal of pharmaceutical sciences, 101(9), 3500-10
Citation
Nofsinger, Rebecca; Borchardt, Ronald T. (2012). Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: Characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P-450 enzymes in the intestinal mucosa.. Journal of pharmaceutical sciences, 101(9), 3500-10. https://doi.org/10.1002/jps.23079